



FOR IMMEDIATE RELEASE

CORE LAB ANNOUNCES THE RESULTS OF ITS 2022 ANNUAL SHAREHOLDER MEETING

AMSTERDAM (19 May 2022) – Core Laboratories N.V. (NYSE: "CLB US" and Euronext Amsterdam: "CLB NA") announces it held its annual shareholder meeting on 19 May 2022 in Amsterdam, The Netherlands. At that meeting, the shareholders re-elected Ms. Martha Carnes and Mr. Michael Straughen and elected Ms. Katherine Murray to the supervisory board. The vote results for all matters voted upon at the annual meeting of shareholders on 19 May 2022 are as follows:

Proposal No. 1 - Election of Class II Directors: The election of each Class II supervisory director was approved as follows:

<u>Nominee</u>	<u>For</u>	<u>Withheld</u>	<u>Broker Non-Votes</u>
Katherine Murray	35,546,114	487,055	3,284,973
Martha Carnes	31,835,708	4,197,461	3,284,973
Michael Straughen	31,857,386	4,175,783	3,284,973

Proposal No. 2 – Appointment of KPMG: The appointment of KPMG as the Company's independent registered public accountants for the fiscal year ending 31 December 2022 was approved as follows:

<u>For</u>	<u>Against</u>	<u>Abstentions</u>	<u>Broker Non-Votes</u>
39,184,051	105,417	28,674	0

Proposal No. 3 - Confirm and Adopt the Dutch Statutory Annual Accounts: The confirmation and adoption of the Company's Dutch Statutory Annual Accounts in the English language for the fiscal year ended 31 December 2021 was approved as follows:

<u>For</u>	<u>Against</u>	<u>Abstentions</u>	<u>Broker Non-Votes</u>
39,114,755	152,327	51,060	0

Proposal No. 4 - Approve and Resolve the Cancellation of Repurchased Shares: The approval of the cancellation of the Company's repurchased shares held by the Company in its name at 12:01 a.m. CEST on 19 May 2022 was approved as follows:

<u>For</u>	<u>Against</u>	<u>Abstentions</u>	<u>Broker Non-Votes</u>
39,128,770	158,734	30,638	0

Proposal No. 5 - Approve Extension - Repurchase up to 10% of Issued Share Capital: The approval of the extension of the existing authority to repurchase up to 10% of the Company's issued share capital until 19 November 2023 was approved as follows:

<u>For</u>	<u>Against</u>	<u>Abstentions</u>	<u>Broker Non-Votes</u>
38,835,452	178,300	304,390	0

Proposal No. 6 - Approve Extension to Issue Shares and/or Grant Rights: The approval of the extension of the authority to issue shares and/or to grant rights (including options to purchase) with respect to the Company's common and preference shares up to a maximum of 10% of outstanding shares per annum until 19 November 2023 was approved as follows:

<u>For</u>	<u>Against</u>	<u>Abstentions</u>	<u>Broker Non-Votes</u>
38,960,491	317,684	39,967	0

Proposal No. 7 - Approve Extension to Limit or Exclude Preemptive Rights: The approval of the extension of the authority to limit or exclude the preemptive rights of the holders of the Company's common shares and/or preference shares up to a maximum of 10% of outstanding shares per annum until 19 November 2023 was approved as follows:

<u>For</u>	<u>Against</u>	<u>Abstentions</u>	<u>Broker Non-Votes</u>
37,646,617	1,629,457	42,068	0

Proposal No. 8a - Approve the Compensation of the Company's Executive Officers: The compensation program regarding the Company's named executive officers was approved, on an advisory basis, as follows:

<u>For</u>	<u>Against</u>	<u>Abstentions</u>	<u>Broker Non-Votes</u>
35,425,951	541,743	65,475	3,284,973

Proposal No. 8b - Approve the Company's Remuneration Report as Referred to in Section 2:135b of the Dutch Civil Code: The remuneration report was approved, on an advisory basis, as follows:

<u>For</u>	<u>Against</u>	<u>Abstentions</u>	<u>Broker Non-Votes</u>
35,422,218	542,482	68,469	3,284,973

For more information contact:
Gwen Y. Gresham - SVP Corporate Development and Investor Relations, +1 713 328 6210
investor.relations@corelab.com

###